Spoken Alpha
Absci Corp
Absci designs antibody-based therapeutics using an AI-native platform that combines generative AI models with lab validation to accelerate drug discovery.
Absci Corp is a Healthcare company operating in Biotechnology with a $1.36B market cap.
ABSI missed consensus EPS by 0.1% in Q2 FY2026, reported Aug 10, 2026.
11 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for ABSI.
$ curl https://api.spokenalpha.com/v1/companies/ABSIFAQ
Spoken Alpha indexes ABSI's earnings call transcripts at https://spokenalpha.com/companies/ABSI. Each call links to attributed speakers and parsed analyst Q&A. Absci Corp's own investor relations page is at https://investors.absci.com/.
Absci Corp (ABSI) held its most recent earnings call on 2026-08-11, covering fiscal Q2 2026.
Absci Corp (ABSI) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-10 | $-0.21 | $-0.20 | -5.0% | $318.0K | — | — | EODHD |
| Q1 FY2026 | 2026-05-06 | $-0.19 | $-0.20 | +5.0% | $215.0K | — | — | EODHD |
| Q4 FY2025 | 2026-03-23 | $-0.23 | $-0.18 | -27.8% | $650.0K | — | — | EODHD |
| Q3 FY2025 | 2025-11-11 | $-0.20 | $-0.21 | +4.8% | $378.0K | — | — | EODHD |
| Q2 FY2025 | 2025-08-11 | $-0.24 | $-0.21 | -14.3% | $593.0K | — | — | EODHD |
| Q1 FY2025 | 2025-05-12 | $-0.21 | $-0.22 | +4.5% | $1.2M | — | — | EODHD |
| Q4 FY2024 | 2025-03-18 | $-0.25 | $-0.22 | -11.7% | $665.0K | — | — | EODHD |
| Q3 FY2024 | 2024-11-11 | $-0.24 | $-0.19 | -26.3% | $1.7M | — | — | EODHD |
| Q2 FY2024 | 2024-08-13 | $-0.22 | $-0.18 | -22.2% | $1.3M | — | — | EODHD |
| Q1 FY2024 | 2024-05-13 | $-0.22 | $-0.20 | -10.0% | $898.0K | — | — | EODHD |
| Q4 FY2023 | 2024-03-20 | $-0.25 | $-0.25 | 0.0% | $338.0K | — | — | EODHD |
| Q3 FY2023 | 2023-11-13 | $-0.24 | $-0.22 | -9.1% | $744.0K | — | — | EODHD |
| Q2 FY2023 | 2023-08-13 | $-0.22 | $-0.24 | +8.3% | $3.4M | — | — | EODHD |
| Q1 FY2023 | 2023-05-14 | $-0.26 | $-0.24 | -8.3% | $1.3M | — | — | EODHD |
| Q4 FY2022 | 2023-03-29 | $-0.21 | $-0.25 | +16.0% | $1.6M | — | — | EODHD |
| Q3 FY2022 | 2022-11-08 | $-0.30 | $-0.28 | -7.1% | $2.4M | — | — | EODHD |
| Q2 FY2022 | 2022-08-10 | $-0.32 | $-0.31 | -3.2% | $1.0M | — | — | EODHD |
| Q1 FY2022 | 2022-05-10 | $-0.33 | $-0.28 | -17.9% | $819.0K | — | — | EODHD |
| Q4 FY2021 | 2022-03-21 | $-0.28 | $-0.25 | -12.0% | $1.5M | — | — | EODHD |
| Q3 FY2021 | 2021-11-08 | $-0.33 | $-0.17 | -94.1% | $1.5M | — | — | EODHD |
Source: EODHD. ABSI reported actuals as published; sparse fields render as —.